How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

738 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

541. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. (Full text)

therapy. The patients were randomly assigned into three study groups: group I, fenproporex 25 mg/d (n = 10); group II, sibutramine 10 mg/d (n = 10); and group III, orlistat 120 mg tid (n = 11). Body fat, measured by dual-energy x-ray absorptiometry, and serum and CSF concentrations of leptin were examined at baseline and 2 months after therapy. At baseline, clinical and biochemical characteristics of the groups were similar. All of the women lost weight, approximately 7.0% of their initial body weight (...) /serum leptin ratio decreased after weight loss in obese women treated during 2 months with orlistat, whereas this ratio did not change in this period of time in obese women treated with fenproporex and sibutramine.

2002 The Journal of clinical endocrinology and metabolism Controlled trial quality: uncertain PubMed abstract

542. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. (Full text)

produced medium effect sizes. Four drugs produced large effect sizes (ie d>0.80; amphetamine, benzphetamine, fenfluramine and sibutramine). The placebo-subtracted weight losses for single drugs vs placebo included in the meta-analysis never exceeded 4.0 kg. No drug, or class of drugs, demonstrated clear superiority as an obesity medication. Effects of methodological factors are also presented along with suggestions for future research.

2002 International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity PubMed abstract

543. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. (Abstract)

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. To investigate the influence of orlistat on the pharmacokinetics of selected concomitant medications (amitriptyline, atorvastatin, cyclosporine, losartan, metformin, phentermine, and sibutramine) at or within two-fold of therapeutic doses, open-label, multiple-dose (for 6 or 7 days), randomized, two-period (except for cyclosporine, for which a three

2002 Journal of clinical pharmacology Controlled trial quality: uncertain

544. Achieving weight-loss maintenance. (Abstract)

, double-blind, placebo-controlled study: Sibutramine Trial of Obesity Reduction and Maintenance--will be described. This study showed that with an individualized weight-management program, most obese patients can achieve metabolically significant weight loss, and this loss can be sustained in most patients who continue therapy for 2 years. New analyses reveal that those patients who maintain a higher level of physical activity do better, and the prediction that blood pressure responses might (...) be hazardous is counteracted by predictive analyses of multiple sibutramine trials, which suggest a likely absolute reduction in cardiovascular risk in sibutramine-treated patients. Additional evidence suggests a reduced cardiovascular load as a result of this new management system, which should be seen as the beginning of a new era in our approach to tackling the hazards of overweight and obesity long term.

2001 Postgraduate medicine Controlled trial quality: uncertain

545. Great expectations: "I'm losing 25% of my weight no matter what you say". (Abstract)

Great expectations: "I'm losing 25% of my weight no matter what you say". This study investigated whether informing obese individuals that they would lose only modest amounts of weight would lead them to adopt more realistic weight loss expectations. At a screening interview, 53 obese women reported that they expected to lose the equivalent of 28% of their initial weight during 1 year of treatment with the medication sibutramine. Prior to beginning treatment, participants were informed, both

2003 Journal of Consulting and Clinical Psychology Controlled trial quality: uncertain

546. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. (Abstract)

One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. The purpose of this study was to evaluate the effects of a combination weight loss program using intermittent low-calorie diets, energy-controlled meal replacement products, and sibutramine on weight loss, diabetes control, and cardiovascular risk factors in overweight or obese subjects with type 2 diabetes.Overweight or obese individuals with type 2 diabetes treated with diet (...) or oral medication were randomly assigned to either a standard therapy or combination therapy group. Both groups received a standardized program to facilitate weight loss. The combination therapy group also received 10-15 mg sibutramine daily, low-calorie diets using meal replacement products for 1 week every 2 months, and between low-calorie diet weeks, once daily use of meal replacement product and snack bars to replace one usual meal and snack. Primary outcome measures were changes in body weight

2003 Diabetes Care Controlled trial quality: uncertain

547. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. (Full text)

sibutramine (n=929) studies met inclusion criteria. Attrition rates averaged 33% in orlistat studies and 48% in sibutramine studies. A random effects model was used for meta-analysis. Compared to placebo, orlistat-treated patients displayed a 2.7 kg (95% CI: 2.3-3.1 kg) or 2.9% (95% CI: 2.3-3.4%) greater reduction in weight and patients on sibutramine displayed a 4.3 kg (95% CI: 3.6-4.9 kg) or 4.6% (95% CI: 3.8-5.4%) greater weight reduction after 1 y of follow-up. The number of patients achieving 10 (...) % or greater weight loss was 12% (95% CI: 8-16%) higher with orlistat and 15% (95% CI: 4-27%) higher with sibutramine compared to placebo. Orlistat caused gastrointestinal side effects and sibutramine increased blood pressure and pulse rate.There is a relative paucity of long-term studies of antiobesity agents. In weight loss trials of 1-y duration, orlistat and sibutramine appear modestly effective in promoting weight loss. Longer, more methodologically rigorous studies that are powered to examine end

2003 International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity PubMed abstract

548. Measurement of 3-methoxy-4-hydroxyphenylglycol (MHPG) in mouse brain by h.p.l.c. with electrochemical detection, as an index of noradrenaline utilisation and presynaptic alpha 2-adrenoceptor function. (Full text)

were decreased after administration of the noradrenaline reuptake inhibitor desipramine (5 and 10 mg kg-1) and the non-selective monoamine reuptake inhibitors, sibutramine HCl (BTS 54 524; 1 and 3 mg kg-1) and amitryptyline (5 mg kg-1). However, the selective 5-hydroxytryptamine reuptake inhibitor, zimeldine (5 and 10 mg kg-1), was without effect. Dexamphetamine (1 and 5 mg kg-1) and methamphetamine (1 and 5 mg kg-1) both decreased brain MHPG concentrations in a dose-related fashion. 6. Overall

1989 British journal of pharmacology PubMed abstract

549. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds (Full text)

-dependent protection against acetic acid-induced abdominal constriction. Similarly, morphine and aspirin were also effective antinociceptive agents in this nociceptive assay. 3. Opioid antagonists, naloxone (0.5 mg kg(-1), s.c.) and naltrindole (1 mg kg(-1), s.c.), shifted the dose-response relationships to the right for each of the antidepressant agents (dothiepin, amitriptyline, sibutramine, (+)-oxaprotiline and paroxetine). In this context the naloxone dose-ratios were 1.95, 3.90, 2.32, 4.50 and 2.65

1998 British journal of pharmacology PubMed abstract

550. Recent developments in the treatment of obesity-related hypertension. (Abstract)

physical exercise can lower blood pressure. Several studies have shown that pharmacologically induced weight reduction with orlistat or sibutramine can likewise be beneficial in the management of obese hypertensive patients. The role of surgery in obesity remains to be defined.Both non-pharmacologically and pharmacologically induced weight loss can lower blood pressure in obese hypertensive patients. The effects of weight loss and pharmacological management on morbidity and mortality in obese

2002 Current Opinion in Nephrology and Hypertension

551. sibutramine

sibutramine sibutramine - General Practice Notebook This site is intended for healthcare professionals General Practice Notebook | Medical search sibutramine blocks noradrenaline and serotonin reuptake in the brain - this effect produces a feeling of satiety after smaller meals (1). It can be described as a serotonin and noradrenaline reuptake inhibitor (2) sibutramine is taken for up to 12 months in conjunction with exercise and diet. It leads to a reduction in weight- and obesity-related co (...) -morbidities (1). The weight reduction is greatest in the first 6 months of treatment (1). The use of sibutramine may also improve glycaemic control and reduce total cholesterol sibutramine undergoes extensive first-pass metabolism in the liver, mainly by cytochrome P450 3A4. Concurrent use of cytochrome P450 inhibitors or inducers may increase or decrease plasma concentrations and thereby increase the unwanted effects or reduce any beneficial effects of sibutramine (2). Also concurrent use of drugs

2010 GP Notebook

552. Cost-effectiveness of sibutramine in the treatment of obesity

Cost-effectiveness of sibutramine in the treatment of obesity Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

553. Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program

Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Malone D C, Raebel M A, Porter J A, Lanty F (...) A, Conner D A, Gay E C, Merenich J A, Vogel E A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sibutramine in conjunction with a weight management programme (WMP) for the treatment of overweight and obese individuals

2005 NHS Economic Evaluation Database.

554. Orlistat and sibutramine beyond weight loss

Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Mannucci E, Dicembrini I, Rotella F, Rotella C M CRD summary This review aimed to assess the effects of orlistat and sibutramine on blood lipids. It concluded that orlistat, but not sibutramine, determined a significant reduction in total cholesterol independent of the weight loss itself. Important information on the methods was missing from the review, so (...) it was impossible to determine whether the conclusions were reliable. Authors' objectives To assess the effects of orlistat and sibutramine on blood lipids independent of weight loss. Searching MEDLINE was searched from inception to the end of May 2005 for relevant English-language articles. Search terms were reported. The reference lists of identified trials and review articles were searched to identify further relevant evidence. Study selection Randomised, double-blind, placebo-controlled trials of six to 12

2008 DARE.

555. The efficacy and safety of sibutramine for weight loss: a systematic review

The efficacy and safety of sibutramine for weight loss: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

556. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Vettor R, Serra R, Fabris R, Pagano C, Federspil G CRD summary This review assessed the effects of sibutramine on weight and glycaemic (...) control in obese patients with type 2 diabetes mellitus. The authors concluded that sibutramine may help to improve glycaemic control because it reduces weight. Inadequate reporting of the quality assessment, characteristics of the included studies, drop-outs and some review methods makes interpretation of the evidence difficult. Authors' objectives To assess the effects of sibutramine on weight and glycaemic control in obese people with type 2 diabetes mellitus. Searching The Cochrane Library

2005 DARE.

557. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany

Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Brennan A, Ara R, Sterz R, Matiba B, Bergemann R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a 1-year course of sibutramine in combination with diet and lifestyle advice for the treatment of obese patients. Sibutramine was initially given at a dosage of 10 mg/day but could be switched to 15 mg/day in the case of non-response at 1 or 3 months. Type

2006 NHS Economic Evaluation Database.

558. The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries

The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

559. Review: orlistat and sibutramine are modestly effective for weight loss at 1 year (Full text)

Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Review: orlistat and sibutramine are modestly effective for weight loss at 1 year | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Article Text Therapeutics Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Free Christopher D Byrne , FRCP

2006 Evidence-Based Medicine PubMed abstract

560. Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes (Full text)

Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Article Text Therapeutics Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Free Christopher

2006 Evidence-Based Medicine PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>